Navigation Links
Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
Date:7/31/2012

ticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal (GI) hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in chronic idiopathic constipation (CIC) patients. In October, 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide to treat CIC. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C), with the first trial in IBS-C patients planned for the second half of 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.

About Plecanatide

Plecanatide is a member of a new class of essentially non-systemic drugs, referred to as guanylate cyclase C (GC-C) agonists, that are currently in development to treat CIC and IBS-C. Plecanatide is a synthetic analog of uroguanylin, a natriuretic hormone that regulates ion and fluid transport in the GI tract. Orally-administered plecanatide binds to and activates GC-C receptors expressed on epithelial cells lining the GI mucosa, resulting in activation of the cystic fibrosis transmembrane conductance regulator (CFTR), and leading to augmented flow of chloride and water into the lumen of the gut. Activation of the GC-C receptor pathway is believed to facilitate bowel movement as well as producing other beneficial physiological responses including improvement in abdominal pain and inflammation. In animal models, oral administration of plecanatide promotes intestinal secretion and also ameliorates GI
'/>"/>

SOURCE Synergy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Research and ... of the  "North America Mammography Market - ...  report to their offering. ... a detailed type of imaging that customs ... A mammography exam, called a mammogram, is ...
(Date:5/27/2015)... Research and Markets ( ... the  "2015 Strategies in the European Hemostasis ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... pages, 120 tables, and is designed to ... identify and evaluate business opportunities emerging in ...
(Date:5/27/2015)... OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts ... a series of diverse complications arising from the presence ... tissues, which cause a rapidly progressing hyperactive host immune ... 50% depending on disease severity. The syndrome places a ... global marketplace, which for the purposes of this report ...
Breaking Medicine Technology:North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2European Hemostasis Diagnostic Testing Market Strategies 2015 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4
... Dec. 20, 2011  As part of a national initiative, the ... with flu vaccination rates for staff of 90 percent or ... . "Increasing vaccination among health care workers is ... the health of all Pennsylvanians," said Secretary of Health Dr. ...
... SPRINGS, Fla., Dec. 20, 2011   Nutra Pharma Corporation ... for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy ... Executive Officer, Rik J. Deitsch, had published a Shareholder ... been very busy here at Nutra Pharma," explained Rik ...
Cached Medicine Technology:Pennsylvania Department of Health Lauds Health Care Facilities for Boosting Flu Vaccination Rates among Workforce 2Nutra Pharma Letter to Shareholders 2
(Date:5/27/2015)... Hills, CA (PRWEB) May 27, 2015 Khanna ... of the art web portal focussed on keratoconus eye ... This relentless progressive disease has its onset in the teenage ... down. The cornea or the front clear part of the ... the pressure in the eye. It results in poor vision ...
(Date:5/27/2015)... New York, New York (PRWEB) May 27, 2015 ... http://www.risperdallawsuit2014.com/ ) filed on behalf of individuals ... other complications related to the use of the ... mass tort litigation currently underway in Pennsylvania’s Philadelphia ... the litigation is proceeding with its bellwether trial ...
(Date:5/27/2015)... In today's healthcare landscape, where costs ... be challenging for doctors and hospitals to keep up ... , Austin-based HealthTronics, Inc. is offering a ... therapies for clinically sophisticated applications. The company has now ... Laser Ventures, Inc ., a mobile laser technology ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ... for enterprise organizations, announced today that SanMar Corporation ... its time, attendance and point tracking processes for ... United States. , Family-owned since 1971, Seattle-based ... retail, private label, and mill brands. SanMar supplies ...
(Date:5/27/2015)... Little Rock, AR (PRWEB) May 27, 2015 ... and Medix today announce a partnership to provide ... the Medix community. This collaboration seeks to strengthen ... skills measurement through CMSA’s CKP program. The mutually ... focused on identifying individual skills of talent in ...
Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3
... of patients with hepatic granulomas have found sarcoidosis and ... granulomas, recent works have noted some patients with chronic ... associations. Today, patients that undergo liver biopsy often have ... possible anti viral therapy. The age of HIV and ...
... used for the relief of fever, headaches, and other ... NSAIDs are well documented and acetaminophen is accepted to ... effects of short-term, especially high-dose NSAID and acetaminophen use ... to be published on November 21 , 2008 in ...
... Dec. 29 Stereotaxis, Inc.,(Nasdaq: STXS ) ... and existing institutional investors to raise gross proceeds of ... in two separate,concurrent transactions. A portion of the warrants ... full, these warrants would provide an additional,approximately $10 million ...
... long-term complications of blood sugar disease, scientists say ... who have gastric bypass surgery not only lose weight ... study finds. , Also called bariatric surgery, the procedure ... thereby reducing the amount of food one can eat. ...
... day in the United States,approximately 10,000 babies are born. On ... across the country welcome their babies,into the world by offering ... Year.,Parents of 2009 New Year,s babies can go to ... Year,s Baby coupons for free Beech-Nut,foods. , ...
... Internet - , , ANTHEM, Ariz., Dec. 29 ... of its new web site at http://www.mychoicedentist.com and ... Phoenix , Arizona, area is proceeding successfully. "Arizona is ... CEO. "We anticipate expanding this service to almost every major ...
Cached Medicine News:Health News:May hepatic granulomas be part of the histological spectrum of chronic hepatitis C? 2Health News:Acute gastric injury due to high-dose analgesics? 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 3Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 4Health News:Gastric Bypass Halts Diabetes in Obese Teens 2Health News:Gastric Bypass Halts Diabetes in Obese Teens 3Health News:Beech-Nut Offers Free Food for Babies Born on January 1, 2009 2Health News:Beech-Nut Offers Free Food for Babies Born on January 1, 2009 3Health News:Prime Companies Announces Launch of New Dental Web Site 2
... The OcuLight family of infrared laser ... SLx models. These diode lasers serve as ... devices and applications, require no regular maintenance ... with their compact design. The OcuLight SLx ...
... mid range space saver specular microscope. It has ... the corneal endothelium automatically. It also has the ... central area. The image of the cells is ... with the system., This model is exactly the ...
... Danker Laboratories manufacturers ... RGP orthokeratology lenses (also ... or "Corneal Reshaping" Lenses) ... specifications and demanding standards ...
... The JSZ Orthokeratology (oprifocon A) ... permeable contact lenses used for ... corrects nearsightedness (myopia). The patient ... removes them in the morning. ...
Medicine Products: